Effects of a Mobile Phone Short Message Service (SMS) on Antiretroviral Treatment Adherence in Kenya (WelTel Kenya1): A Randomized Trial Jesse Coleman.

Slides:



Advertisements
Similar presentations
A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.
Advertisements

Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.
Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
Intro mHealth The practice of medicine and public health supported by mobile devices has emerged in recent years for developing countries as a means of.
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
A case series of ART-associated gynaecomastia reported to the National HIV & TB Healthcare Workers (HCW) hotline Christine Njuguna. Division of Clinical.
Integrating Evidence-Based Practice Into QI to Improve Patient Outcomes in HIV: Viral Load Suppression Victoria Lieb, ACRN, MPH; Carla Rossi, MD; Jaime.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Dr. Yogan Pillay Deputy Director General National Department of Health, South Africa Monday 1 July 2013 OPERATIONAL AND PROGRAMMATIC CONSIDERATIONS IN.
Peripartum Valacyclovir Improves Markers of HIV-1 Disease Progression in Women Co-Infected with HSV-2: A Randomized Trial Alison C. Roxby, MD, MSc. July.
Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.
When are reminders for behavior modification effective? Experimental evidence from the use of text messages to improve medication adherence James Habyarimana.
Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.
PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV WHAT’S NEW Prepared by Dr. Debbie Carrington National HIV/AIDS Prevention & Control Programme Ministry.
Involving the Community in HIV/AIDS Treatment Support Programmes: An Evidence-Based Approach.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
JNB/05 HIV/AIDS treatment - challenges in a remote rural area of Tanzania. Johan N. Bruun Department of Infectious Diseases Ullevål University Hospital.
Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.
Quality Assessment and Improvement Harvard – PEPFAR Tanzania, Nigeria and Botswana.
Quality of Care at a Multi-site PEPFAR-funded ART Program: From Measuring to Improvement.
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
Supporting adherence to antiretroviral therapy with mobile phone reminders in South India Rashmi Rodrigues Jimmy Antony, Kristi Sidney, Karthika Arumugam,
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
Review on current technology HIV/AIDS care and control Will Mobile Technology "Do It"? Review on current technology Richard Lester, MD, FRCPC BCCDC / University.
Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.
ART for Prevention From Evidence to Action Wafaa El-Sadr, MD, MPH ICAP-Columbia University.
Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo- controlled trial in Rakai, Uganda Steven J.
Designing a mobile health intervention for diabetes management in India Fiona Y. Akhtar MBA, MS | Mobile Health Design | June 10, 2013
Antiretroviral Treatment Monitoring: A Canadian Case Example Antiretroviral Treatment Monitoring: A Canadian Case Example Robert Hogg, PhD BC Centre for.
UNITED STATES CONFERENCE ON AIDS MONDAY, SEPTEMBER 9, 2013 NEW ORLEANS, LA Will Community Involvement in Test Link to Care, Plus Treat Research (HPTN 065)
Challenges to replacing CD4 testing with viroloigical monitoring Andrew Hill, Pharmacology Research Laboratories, University of Liverpool, UK World AIDS.
Community-based Adherence Clubs improve outcomes for stable ART patients: Outcomes from Cape Town, South Africa Anna Grimsrud 1, Maia Lesosky 1,2, Cathy.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
Results Compliance with Breast Cancer Screening Guidelines in the HIV Clinic: A Quality Improvement Tool E. Patrozou M.D., E. Christaki M.D., L. Hicks.
The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children Heidi M.
MHealth Working Group April 20, 2011 Held at FHI.
1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.
“Effects of an HIV-Care-Program on the health- Status of HIV- positive patients in jaoundé, Cameroon“: a cluster- randomized trial Indo- Global Summit.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
Effect of High-Dose HSV-2 Suppressive Therapy on Plasma HIV-1 RNA levels: a randomized, cross over trial 6 th IAS conference, Rome, Italy th July,
Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.
Alison Drake International AIDS Society Conference July 18, 2011 Valacyclovir suppression reduces breast milk and plasma HIV-1 RNA postpartum: results.
HIV Testing for TB Patients in the Context of ART Scale-Up - Barriers to Implementation Kevin M. De Cock, MD CDC Kenya Geneva, February 14, 2005.
World Health Organization | Viet Nam Country Office1 Enhancing Benefits of Early Antiretroviral Therapy Evidence, Implication and Preliminary Findings.
PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
An Oak Tree Clinic & BCCDC partnership “Partnerships make a difference”
Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.
Cumulative plasma HIV-1 level as a novel tool to evaluate antiretroviral therapy efficacy at the individual and public health levels Presented by Viviane.
WAD SYMPOSIUM 2014 ART Adherence and Retention: MDH Experience Eric Aris Management and Development for Health 29 th November 2014 NJOMBE.
Paz Bailey G 1, Sternberg M 1, Puren AJ 2, Markowitz LE 1, Ballard R 1, Delany S 3, Hawkes S 4, Nwanyanwu O 1, Ryan C 1, and Lewis DA 5 1. NCHHSTP, CDC.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.
Review of mHealth evidence:
Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.
Evidence based mHealth for patient engagement in care
1University of Maryland; 2Futures Group International; 3CDC; 4USAID
MHEALTH to Improve Health: Effectiveness of a weekly text messaging intervention to improve ART adherence and HIV Viral Load: WelTel OAKTREE. M.C.M. Murray1,2,3,
The use of cotrimoxazole prophylaxis in the context of HIV infection
Frank Chirowa, Nicoletta Ngorima-Mabhena, Owen
HIV Quality Improvement (QI) and the Treatment Cascade: How QI has Impacted Reach, Recruitment, Testing, Treatment, and Retention Efforts in Thailand?
Dr. Velephi Okello, Principal Investigator, MaxART Trial
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
Retention: What It Means for You
Summary Sheet Figures and Maps
Presentation transcript:

Effects of a Mobile Phone Short Message Service (SMS) on Antiretroviral Treatment Adherence in Kenya (WelTel Kenya1): A Randomized Trial Jesse Coleman University of British Columbia, BC Centre for Disease Control ICIUM, Antalya, Turkey Nov 14, 2011 Original research by Dr. Richard Lester et al. Your health, in your hands

Kenya Clinic Survey, July 2005 Despite often making <$2/day… Most patients had cell phone access Most patients attending HIV clinics had cell phone access Used for almost everything… But not used for health management Lester et al. AIDS Vol 20, 17 Nov, 2006 The Unfortunate Gap

Hypothesis: cell phone communicationwill improve: The cell phone intervention (SMS), through regular communication with patients, will improve: ART adherence (30 day self-report at 6 and 12m) HIV plasma viral suppression (<400 copies/ml) at 12m Also, health, social, and economic outcomes... Compared to the current standard of care (SOC) The PHE: WelTel Kenya1 Clinical Trial (NCT )

*Protocol: SMS (text messaging) SMS: “Mambo? = How RU?” “Sawa” = Fine “Shida” = Problem Monday <48h If necessary HealthAdvice SMS ‘check-in’ SMS response *Derived from focused group discussions with HCW and patients

Study Participants and Randomization Screening (581+) Randomized (538) Pumwani (251) SMS (120) Follow-up control (131) Follow-up Coptic (209) SMS (117) Follow-up control (92) Follow-up Kajiado (78) SMS (36) Follow-up control (42) Follow-up Inclusion Adults (> 18 years) starting ART Adequate phone access (owned/shared) Informed consent Randomization Baseline survey 6 month 12 month Powered to show 10% improvement in adherence Exclusion (44) Inadequate phone access Refused/Unable SMS n=273 Control n=265

Patient Characteristics =Equity 65% women 65% women Median age 36 Oldest age = 82 Oldest age = 82 30% unemployed 30% unemployed no formal education 4.5% had no formal education (26% at rural site) CD4 = % ‘rural’ 30% make < $1 per day 30% make < $1 per day =Access Cell phone access – 84% owned – 84% owned cell phone – 16% shared – 16% shared a phone – 0.3% had a land line – Distance from clinic 83% never called clinic before study...

Weekly (SMS) Patient Response Rates Weekly (SMS) Patient Response Rates n=11,983 SMS logs (6.1% ‘SHIDA’) (2.0% ‘SHIDA’)

Feedback Positive feedbackChallenges “Feels like someone cares” 98% want the program to continue 97% would recommend it to a friend SMS response rates Changes in phone ownership Crisis management Scalability? Scalability? Why Why does it work? – Behavior change? – Reminders? Lester & Karanja Lancet Infectious Diseases Vol 8 December 2008

Study Conclusions Cell phones useful for HIV/AIDS management SMS patient support significantly improved ART adherence and rates of viral suppression (First report) – SMS patients 24% more likely to be adherent to ART – SMS patients 19% more likely to have suppressed VL Logistical challenges can be overcome equitable access May enhance equitable access to care Implications for developing health systems (horizontal?) outreach-improves-hiv

Example Kenya PEPFAR investment in HIV /AIDS (2010) $548,119,441 $548,119,441 (includes treatment and prevention efforts) 410,300 individuals on ART 410,300 individuals on ART Apply WelTel = 37,300 Apply WelTel = 37,300 extra people with fully suppressed HIV load Cost, est. <1% of PEPFAR spending Kenya Government Investment in Health $513,000,000 on health $513,000,000 on health HIV prevalence 6.3% WelTel 24% improvement in ART adherence (19% in VL) 1.2-7% reduction in TOTAL health services cost = 1.2-7% reduction in TOTAL health services cost WelTel = gov’t savings of $5-36,000,000 USD WelTel = gov’t savings of $5-36,000,000 USD Model REF: Freedberg K et al. Cote d’Ivoire, PLoS Med 2009 Model REF: Freedberg K et al. Cote d’Ivoire, PLoS Med 2009

PEPFAR: Costs and savings from WelTel (draft) ARV Patients on WeltelYear 1Year 2Year 3 Percent of total60%70%80% Numbers 1,491, ,739, ,988, Year 1Year 2Year 3 Total Costs Saved $ 49,192, $ 53,685, $ 95,234, Costs of Weltel $ 30,051, $ 23,759, $ 23,430, Year 1Year 2Year 3 Costs Saved of 2nd Line therapy $ 16,036, $ 18,709, $ 21,381, Costs Saved of Opportunistic Infections $ 49,090, $ 57,272, $ 65,454, Costs Saved for Clinic Time Needed $ 53,633, $ 53,626, $ 143,079, Total Costs Saved $ 118,760,764 $ 129,608,225 $ 229,915,685

Concluding statements support) improve HIV treatment outcomes mHealth (Cell Phone SMS support) can improve HIV treatment outcomes in resource- limited settings May benefit HIV pandemic control (helps Treatment as Prevention) cost-containment Global AIDS response cost-containment Post – trial obligation to implement.